Drug delivery systems improve pharmaceutical profile and facilitate medication adherence

Advances in Therapy

Volumn 22, Issue 6, 2005, Pages 559-577

  Wertheimer, Albert I ^a   Santella, Thomas M ^a   Finestone, Albert J ^b,c   Levy, Richard A ^d  

^a TEMPLE UNIVERSITY   (United States)

^b Department of Medicine ^*

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Levy Consulting   (United States)

Author keywords

Adherence; Cost effectiveness; Dosage forms; Drug delivery; Medication technology

Indexed keywords

ADVAIR DISKUS; ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CARMUSTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; CYCLOSPORIN; DIURETIC AGENT; DORZOLAMIDE; DOXORUBICIN; FENTANYL; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCERYL TRINITRATE; GONADORELIN; LIDOCAINE; LIPOSOME; MACROGOL; METHYLPHENIDATE; NICOTINIC ACID; NIFEDIPINE; OPIATE; OXYBUTYNIN; POLYMER; PULMICORT RESPULE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOMATOSTATIN DERIVATIVE; TESTOSTERONE; UNINDEXED DRUG; VERAPAMIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHMA; ATTENTION DEFICIT DISORDER; BLURRED VISION; BRAIN TUMOR; CARDIOTOXICITY; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG FORMULARY; DRUG FORMULATION; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GLAUCOMA; HEPATITIS C; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; KAPOSI SARCOMA; PATIENT COMPLIANCE; PROSTATE CANCER; PSORIASIS; REVIEW; SIDE EFFECT; URGE INCONTINENCE; XEROSTOMIA;

DOSAGE FORMS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; PRESCRIPTION FEES; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645020197     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849950     Document Type: Review

References (65)

1. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov. 2005;4:381-385.
2. Chien W, Lin S. Optimisation of treatment by applying programmable rate-controlled drug delivery technology. Clin Pharmacokinet. 2002;41:1267-1299.
3. Brookoff D. Chronic pain. 2. The case for opioids. Hosp Pract. 2000;35:69-84.
4. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use of opioid analgesics. JAMA. 2000;283:1710-1714.
5. Carruthers G, Turgeon J. The pharmacokinetics of calcium channel blockers for the treatment of hypertension: an expert interview with George Carruthers, MD and Jacques Turgeon, BPharm, PhD. Medscape posted 8/25/2005. Available at: http://www.medscape.com/viewarticle/510930. Accessed October 27, 2005.
6. Wertheimer A, Levy R, O'Connor T. Too Many Drugs? The Clinical and Economic Value of Incremental Innovations (Executive Summary). Reston, Va: The National Pharmaceutical Council; 2001.
7. Prisant LM. Chronobiol Hypertens Med Crossfire. 1999;1:1-16.
8. Wertheimer A, Levy R, O'Connor T. Investing in Health: The Social and Economic Benefits of Health Care Innovation. Reston, Va: The National Pharmaceutical Council; 2001:77-118.
9. Ratey J. An update on medications used in the treatment of attention deficit disorder-1999. Focus. Available at: http://www.johnratey.com/Articles/ An%20Update%20On%20Medications %20Used%20In%20The%20Treatment%20Of%20ADHD.pdf. Accessed September 10, 2005.
10. McKenney J, Proctor J, Harris S, Chinchili V. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
11. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release-A review of its use in the management of overactive bladder. Drugs. 2004;64:885-912.
12. Dmochowski R, Davila W, Zinner N, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586.
13. Gulliver WP, Murphy GF, Hannaford VA, Primmett D. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporine. Br J Dermatol. 1996;(suppl 135):35-39.
14. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgium cost-effectiveness analysis. Pharmacoeconomics. 2005;23(suppl 1):35-47.
15. Theodouolu M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100:2052-2054.
16. Patton JS, Bossard MJ. Drug delivery strategies for proteins and peptides from discovery and development to life cycle management. Drug Deliv Technol. 2004;4. Available at: http://www.drugdeliverytech.com/cgi-bin/articles.cgi? idArticle=261. Accessed December 28, 2005.
17. Westphal M, Hilt DC, Bortley E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 2003;5:79-88.
18. Gliadel information for professionals. Available at: http://www.gliadel. com/professional/ efficacy.htm#. Accessed October 28, 2005.
19. Dwyer MS, Levy R, Menander KW. Improving medication compliance through the use of modern dosage forms. J Pharmaceut Technol. 1986;2:166-170.
20. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension-the cycle repeats. Drugs. 2002;62:443-462.
21. Fechtner RD, Realini TB. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132-135.
22. Dunbar JJ, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54(suppl 1):s57-s60.
23. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2000;2: CD000011.
24. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta analysis. Med Care. 1998;36:1138-1161.
25. Ellis S, Shumaker S, Sieber W, Rand C. Adherence to pharmacological interventions. Current trends and future directions. Control Clin Trials. 2000;21(5 suppl):218-225.
26. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
27. Benner JS, Glynn RJ, Mogun H, Neuman PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
28. Haynes RB. Improving patient adherence: state of the art, with a special focus on medication taking for cardiovascular diseases. In: Burke LE, Ockene IS, eds. Compliance in Healthcare and Research. Armonk, NY: Futura Publishing Co.; 2001:3-21.
29. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med. 2000;160:2129-2134.
30. Wang TD, Sarocco P, Newmann P, Weinstein MC. Health and economic burden of poor medication adherence in the United States (abstract). Value Health. 2005;8:267.
31. Hite M. Improving adherence in the polypharmacy management of disease. Business Briefing: Pharmatech. 2004:1-4.
32. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24:302-316.
33. Fairley CK, Permana A, Read T. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med. 2005;6:366-369.
34. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185-190.
35. Smart T. Once-a-day dosing: balancing convenience and effectiveness. In: The Body-The Complete HIV/AIDS Resource. Available at: http://www.thebody.com/ cria/winter03/once_a_day.html. Accessed December 28, 2005.
36. Recher RR, Gallagher R, Amonkar M, Smith JC, MacCosbe PE. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. Presented at: 26th Annual Meeting of the American Society for Bone Mineral Research; October 1-5, 2004; Seattle, Wash. Poster SA407.
37. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? Presented at: 26th Annual Meeting of the American Society for Bone Mineral Research; October 1-5, 2004; Seattle, Wash. Poster M434.
38. Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. Presented at: 26th Annual Meeting of the American Society for Bone Mineral Research; October 1-5, 2004; Seattle, Wash. Poster M423.
39. Leichter SB, Thomas S. Combination medications in diabetes care: an opportunity that merits more attention. Clin Diabetes. 2003;21:175-178.
40. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460-467.
41. McMahon G, Jain A, Vargas R. A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension. Clin Ther. 1990;12:88-100.
42. Weidler D, Wallin J, Cook E, Dillard D, Lewin A. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. J Clin Pharmacol. 1992;32:444-449.
43. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9(9 suppl):S2-S6.
44. Pots R, Lobo R. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. Obstet Gynecol. 2005;105(5, part 1):953-961.
45. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285:2347-2354.
46. Gates B. Recent advances in contraceptive therapy. Adv Pharmacol. 2002;1:46-57.
47. Chui MA, Williamson T, Arciniego J, et al. Patient persistency with medications for overactive bladder (abstract). Value Health. 2004;7:366.
48. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface. 2004;17:54-60.
49. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8:495-505.
50. Zlotnick S, Prince T, Frenchman IB. Cost analysis of immediate- versus controlled-release medication administration in long-term care. Consult Pharm. 1996;11:689.
51. Cramer MP, Saks SR. Translating safety, efficacy, and compliance into economic value for controlled release dosage forms. Pharmacoeconomics. 1994;5:482-504.
52. Edwards N, Rupnow M, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics. 2005;23:299-314.
53. Rey JA. Antipsychotic therapy: a pharmacoeconomic perspective. Am J Health Syst Pharm. 2002;59(suppl 8):S5-S9.
54. Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm. 2004;61:1792-1800.
55. Laux G, Heeg BM, Van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23(suppl 1):49-61.
56. Chue PS, Heeg BM, Buskens E, Van Hout BA. Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada 2005. Pharmacoeconomics. 2005;23(suppl 1):62-74.
57. Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics. 2004;22:1047-1059.
58. Mort M. Multiple modes of drug delivery-technologies such as microchips and microspheres are enabling the therapeutic use of proteins. Mod Drug Discov. 2000;3:30-32,34.
59. Cefalu WT, Balagtas CT, Landschulz WH, Gelfand RA. Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy. Diabetes. 2000;49(suppl 1):A406.
60. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331-335.
61. Rosenstock J. Mealtime rapid-acting inhaled insulin (Exubera®) improves glycemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomized, comparative trial for the Exubera® phase III study group. Paper (A132) published in: American Diabetes Association Diabetes Abstract Book for the 62nd Scientific Sessions; June 15-17, 2002; San Francisco, Calif.
62. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001;134:203-207.
63. Hollander P. Efficacy and safety of inhaled insulin (Exubera®) compared to sc insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial, for the Exubera phase III study group. Poster presented at: President's Poster Session of the American Diabetes Association 61st Scientific Sessions; June 22-26, 2001; Philadelphia, Pa.
64. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-428.
65. Sclar A, Skaer TL. Pharmaceutical formulation and healthcare expenditures. Pharmacoeconomics. 1992;2:267-269.